Atre­ca holds off de­vel­op­ment on its on­ly clin­i­cal pro­gram, cuts head­count by 40%

In a bid to ex­tend its cash run­way, Atre­ca has sus­pend­ed the clin­i­cal de­vel­op­ment of its sol­id tu­mor mon­o­clon­al an­ti­body ATRC-101, slash­ing staff num­bers by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER